Are Lonza Group's (VTX:LONN) Statutory Earnings A Good Guide To Its Underlying Profitability?

Statistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. However, sometimes companies receive a one-off boost (or reduction) to their profit, and it's not always clear whether statutory profits are a good guide, going forward. Today we'll focus on whether this year's statutory profits are a good guide to understanding Lonza Group (VTX:LONN).

It's good to see that over the last twelve months Lonza Group made a profit of CHF658.0m on revenue of CHF5.72b. In the chart below, you can see that its profit and revenue have both grown over the last three years, although its profit has slipped in the last twelve months.

View our latest analysis for Lonza Group

SWX:LONN Income Statement, January 8th 2020
SWX:LONN Income Statement, January 8th 2020

Not all profits are equal, and we can learn more about the nature of a company's past profitability by diving deeper into the financial statements. This article will discuss how unusual items have impacted Lonza Group's most recent profit results. That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

Advertisement

The Impact Of Unusual Items On Profit

To properly understand Lonza Group's profit results, we need to consider the CHF143m expense attributed to unusual items. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And that's hardly a surprise given these line items are considered unusual. If Lonza Group doesn't see those unusual expenses repeat, then all else being equal we'd expect its profit to increase over the coming year.

Our Take On Lonza Group's Profit Performance

Unusual items (expenses) detracted from Lonza Group's earnings over the last year, but we might see an improvement next year. Based on this observation, we consider it likely that Lonza Group's statutory profit actually understates its earnings potential! And on top of that, its earnings per share have grown at 29% per year over the last three years. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. Obviously, we love to consider the historical data to inform our opinion of a company. But it can be really valuable to consider what other analysts are forecasting. Luckily, you can check out what analysts are forecsting by clicking here.

Today we've zoomed in on a single data point to better understand the nature of Lonza Group's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

About SWX:LONN

Lonza Group

Operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally.

Solid track record and good value.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1155.3% undervalued
50 users have followed this narrative
2 users have commented on this narrative
9 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7719.9% undervalued
69 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9217.2% undervalued
23 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$1907.4% undervalued
24 users have followed this narrative
0 users have commented on this narrative
11 users have liked this narrative

Updated Narratives

CL
Clive_Thompson
6831 logo
Clive_Thompson on Green Tea Group ·

One of China's Fastest-Growing Restaurant Chains Trades on Just 7x Earnings and an 8% Dividend

Fair Value:HK$8.728.0% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AZ
PRG logo
aziz_22khi on PRG Holdings Berhad ·

WHERE DID THE SIX MILLION SHARES GO? THE PRG OWNERSHIP TRAIL INVESTORS CANNOT IGNORE

Fair Value:RM 0.4477.3% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BR
Brunhilde_Wagner
CPRT logo
Brunhilde_Wagner on Copart ·

Compounder to Cash Generator in Real Time

Fair Value:US$2710.3% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.917.3% undervalued
85 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28029.8% undervalued
193 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.7% undervalued
72 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0
AN
CSMG3 logo
andre_k1tsg on Companhia de Saneamento de Minas Gerais ·

Gostei

0
|
0